Clinical Cancer Research

Journal

Publication Venue For

  • A quantitative centrosomal amplification score predicts local recurrence of ductal carcinoma in situ.  26:2898-2907. 2020
  • A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific Apoptosis.  26:2711-2724. 2020
  • Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial.  26:1586-1594. 2020
  • Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies a C.  26:1247-1257. 2020
  • Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.  25:7078-7088. 2019
  • Genetic characterization and prognostic relevance of acquired uniparental disomies in cytogenetically normal acute myeloid leukemia.  25:6524-6531. 2019
  • A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma.  25:5799-5807. 2019
  • Advancing drug development in gynecologic malignancies.  25:4874-4880. 2019
  • Arylsulfonamide 64B inhibits hypoxia/ HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.  25:2206-2218. 2019
  • E3611—A randomized phase II study of ipilimumab at 3 or 10 mg/kg alone or in combination with high-dose interferon-a2b in advanced melanoma.  25:524-532. 2019
  • MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials.  25:1809-1816. 2019
  • Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma..  25:73-79. 2019
  • Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) Identifies prognostic biomarkers and DLL3 as a relevant therapeutic target.  25:210-221. 2019
  • Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer.  24:6433-6446. 2018
  • Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX.  24:6204-6211. 2018
  • Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.  24:6471-6482. 2018
  • Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFB1 axis.  24:6078-6097. 2018
  • IFNL4-ΔG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer.  24:5471-5481. 2018
  • Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma.  24:5250-5260. 2018
  • High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling.  24:4309-4318. 2018
  • Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.  24:3632-3643. 2018
  • Accuracy of a novel handheld wireless platform for detection of cardiac dysfunction in anthracycline-exposed survivors of childhood cancer.  24:3119-3125. 2018
  • Discovery and validation of circulating biomarkers of colorectal adenoma by high-depth small RNA sequencing.  24:2092-2099. 2018
  • Lymph node metastases in colon cancer are polyclonal.  24:2214-2224. 2018
  • Early assessment of lung cancer immunotherapy response via circulating tumor DNA.  24:1872-1880. 2018
  • Macropinocytosis of bevacizumab by glioblastoma cells in the perivascular niche affects their survival.  23:7059-7071. 2017
  • Targeting RNA-polymerase I in both chemosensitive and chemoresistant populations in epithelial ovarian cancer.  23:6529-6540. 2017
  • Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues.  23:6351-6363. 2017
  • Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer.  23:4693-4703. 2017
  • Sensitivity and specificity of cetuximab-IRDye800CW to identify regional metastatic disease in head and neck cancer.  23:4744-4752. 2017
  • NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer.  23:4055-4065. 2017
  • Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer.  23:3537-3543. 2017
  • CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ACRIN and GOG study.  23:3684-3691. 2017
  • Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone.  23:3544-3551. 2017
  • A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network trial HCRN 12-157.  23:3003-3011. 2017
  • BAI1 orchestrates macrophage inflammatory response to HSV infection-implications for oncolytic viral therapy.  23:1809-1819. 2017
  • Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors.  23:1852-1861. 2017
  • Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy.  23:658-665. 2017
  • Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapy.  23:342-350. 2017
  • Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase.  22:6256-6265. 2016
  • Current and emerging clinical applications of multispectral optoacoustic tomography (MSOT) in oncology.  22:3432-3439. 2016
  • Notch1 signaling regulates the aggressiveness of differentiated thyroid cancer and inhibits SERPINE1 expression.  22:3582-3592. 2016
  • Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.  22:2545-2554. 2016
  • Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas.  22:1011-1017. 2016
  • Germline variants in asporin vary by race, modulate the tumor microenvironment, and are differentially associated with metastatic prostate cancer.  22:448-458. 2016
  • Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6.  22:405-414. 2016
  • Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.  21:5619-5629. 2015
  • Missed Opportunities and Lost Lives: Consequences of Some Proposed Changes to Regulations on Research with Human Tissues-Letter.  21:5404-5405. 2015
  • Targeting acidity in pancreatic Adenocarcinoma: Multispectral Optoacoustic tomography detects ph-low insertion peptide probes in vivo.  21:4576-4585. 2015
  • Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer.  21:3658-3666. 2015
  • Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019.  21:2771-2779. 2015
  • TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer.  21:2722-2729. 2015
  • Biology of Human Tumors Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.  21:2591-2600. 2015
  • IL2 inducible T-cell kinase, a novel therapeutic target in Melanoma.  21:2167-2176. 2015
  • Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.  20:6314-6323. 2014
  • An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.  20:5918-5926. 2014
  • Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.  20:6083-6095. 2014
  • Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.  20:5456-5467. 2014
  • Toward a drug development path that targets metastatic progression in osteosarcoma.  20:4200-4209. 2014
  • A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.  20:3581-3588. 2014
  • CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to minnelide.  20:2388-2399. 2014
  • Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.  20:890-903. 2014
  • Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: A report from the childhood cancer survivor study.  20:904-911. 2014
  • Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A university of chicago phase 2 consortium trial.  20:490-498. 2014
  • NSAIDs inhibit tumorigenesis, but how?.  20:1104-1113. 2014
  • αb-crystallin: A novel regulator of breast cancer metastasis to the Brain.  20:1-12. 2014
  • ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).  19:6597-6604. 2013
  • Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.  19:6484-6494. 2013
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer.  19:5505-5512. 2013
  • Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.  19:4951-4960. 2013
  • PARP-1 regulates resistance of pancreatic cancer to trail therapy.  19:4750-4759. 2013
  • The prognostic value of MicroRNAs varies with patient race/ethnicity and stage of colorectal cancer.  19:3955-3965. 2013
  • PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer.  19:2342-2354. 2013
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.  19:900-908. 2013
  • Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.  19:170-182. 2013
  • Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.  18:6623-6633. 2012
  • Ursolic acid inhibits growth and metastasis of human, colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: Chemosensitization with capecitabine.  18:4942-4953. 2012
  • The quest for self-identity: Not all cancer stem cells are the same.  18:3495-3498. 2012
  • A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.  18:3440-3451. 2012
  • MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.  18:3030-3041. 2012
  • SSBP2 variants are associated with survival in glioblastoma patients.  18:3154-3162. 2012
  • A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.  18:2032-2038. 2012
  • Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.  18:1092-1100. 2012
  • Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.  18:869-881. 2012
  • High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.  17:6542-6552. 2011
  • PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.  17:6563-6573. 2011
  • Stem cell quiescence.  17:4936-4941. 2011
  • A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.  17:2679-2692. 2011
  • Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.  17:2159-2169. 2011
  • SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.  17:1382-1393. 2011
  • Exosomes and cancer: A newly described pathway of immune suppression.  17:959-964. 2011
  • Serum biomarker panels for the detection of pancreatic cancer.  17:805-816. 2011
  • Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.  17:538-549. 2011
  • Molecular targeting of neural cancer stem cells: TTAGGG, you're it!.  17:3-5. 2011
  • Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.  16:5908-5913. 2010
  • A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.  16:5277-5287. 2010
  • Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.  16:4864-4875. 2010
  • NF1 inactivation in adult acute myelogenous leukemia.  16:4135-4147. 2010
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.  16:3057-3066. 2010
  • Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.  16:2890-2898. 2010
  • Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.  16:2443-2449. 2010
  • Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.  16:1924-1937. 2010
  • Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.  15:7175-7185. 2009
  • Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.  15:6763-6770. 2009
  • Identification of a novel small molecule HIF-1α translation inhibitor.  15:6128-6136. 2009
  • Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.  15:5396-5403. 2009
  • Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.  15:5032-5039. 2009
  • Preclinical drug development must consider the impact on metastasis.  15:4529-4530. 2009
  • Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.  15:4058-4065. 2009
  • Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.  15:4131-4137. 2009
  • Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.  15:4114-4122. 2009
  • In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.  15:3511-3518. 2009
  • Prognostic significance of p53 Codon 72 polymorphism differs with race in colorectal adenocarcinoma.  15:2406-2416. 2009
  • Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: Role of calmodulin.  15:1288-1296. 2009
  • Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma.  14:8052-8060. 2008
  • BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.  14:6198-6206. 2008
  • Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth.  14:5437-5446. 2008
  • Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.  14:4843. 2008
  • Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression.  14:4694-4704. 2008
  • Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: Implications for proliferation and migration in vitro and metastasis in vivo.  14:4961. 2008
  • Telomere maintenance in laser capture microdissection - Purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.  14:4971. 2008
  • A fiber-modified mesothelin promoter-based conditionally replicating adenovirus fortreatment of ovarian cancer.  14:3582-3588. 2008
  • Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses.  14:3299-3305. 2008
  • Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.  14:3052-3059. 2008
  • Pretreatment with cisplatin enhances E7-Specific CD8+ T-cell -mediated antitumor immunity induced by DNA vaccination.  14:3185-3192. 2008
  • Endoglin (CD105): A marker of tumor vasculature and potential target for therapy.  14:1931-1937. 2008
  • Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.  14:2180-2189. 2008
  • A self-quenched galactosamine-serum albumin-rhodaminex conjugate: A "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases.  13:6335-6343. 2007
  • Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.  13. 2007
  • Combination treatment with TRA-8 anti-death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.  13. 2007
  • Pseudohypoxic pathways in renal cell carcinoma.  13:4667-4671. 2007
  • The development and characterization of a human midgut carcinoid cell line.  13:4704-4712. 2007
  • Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.  13:3033-3042. 2007
  • A mosaic fiber adenovirus serotype 5 vector containing reovirus σ1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.  13:2777-2783. 2007
  • Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.  13:2512-2518. 2007
  • Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.  13:1611-1619. 2007
  • β2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis.  12:7294-7305. 2006
  • Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients.  12:6702-6708. 2006
  • Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration.  12:6331-6336. 2006
  • Insulin-like growth factor-I axis as a pathway for cancer chemoprevention.  12:5611-5614. 2006
  • Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.  12:5491-5495. 2006
  • Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.  12:5142-5150. 2006
  • Metastasis suppressor proteins: Discovery, molecular mechanisms, and clinical application.  12:3882-3889. 2006
  • Decreased pigment epithelium-derived factor expression in human breast cancer progression.  12:3510-3517. 2006
  • Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy.  12:2716-2729. 2006
  • Kinetics of metastatic breast cancer cell trafficking in bone.  12:1431-1440. 2006
  • Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.  12:1292-1298. 2006
  • The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: Pharmacokinetic relationship between expired13CO 2 and plasma [2-13C] dihydrouracil.  12:549-555. 2006
  • Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines..  12:4147-4153. 2006
  • Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects.  11:8773-8781. 2005
  • Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.  11:8180-8185. 2005
  • High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.  11:5920-5927. 2005
  • Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.  11:4168-4175. 2005
  • Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling.  11:3668-3677. 2005
  • A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.  11:1327-1335. 2005
  • Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.  11:1342-1347. 2005
  • Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.  11:1073-1085. 2005
  • Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.  10:8603-8612. 2004
  • Expression and functional role of CCR9 in prostate cancer cell migration and invasion.  10:8743-8750. 2004
  • ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.  10:7555-7565. 2004
  • Mesothelin: A new target for immunotherapy (multiple letter) [1].  10:8751-8752. 2004
  • Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.  10:5643-5646. 2004
  • Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.  10:5403-5417. 2004
  • Use of replicating oncolytic adenoviruses in combination therapy for cancer.  10:5299-5312. 2004
  • Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth.  10:5187-5201. 2004
  • Promoter hypermethylation profile of kidney cancer.  10:3972-3979. 2004
  • Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor.  10:3189-3194. 2004
  • Nuclear Localization of KLF4 Is Associated with An Aggressive Phenotype in Early-Stage Breast Cancer.  10:2709-2719. 2004
  • Prognostic Significance of p27kip-1 Expression in Colorectal Adenocarcinomas Is Associated with Tumor Stage.  10:1743-1752. 2004
  • Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models.  10:1263-1273. 2004
  • Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.  9:3731-3741. 2003
  • Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model..  9:3731-3741. 2003
  • Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.  9:2701-2710. 2003
  • CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.  9:619-624. 2003
  • A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.  8:3092-3099. 2002
  • A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: Breast tissue, imaging, and serum and urine biomarkers.  8:3105-3117. 2002
  • Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.  8:734-744. 2002
  • A phase I study of combined modality90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.  8:2806-2811. 2002
  • Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents.  8:202-209. 2002
  • Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.  8:2782-2787. 2002
  • Altered subcellular localization of Suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas.  7:3495-3503. 2001
  • Resveratrol causes WAF-1/p21-mediated G1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.  7:1466-1473. 2001
  • Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.  7:2057-2066. 2001
  • Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.  7:935-941. 2001
  • Expression of human endogenous retrovirus K envelope transcripts in human breast cancer.  7:1553-1560. 2001
  • Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.  7:691-703. 2001
  • Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer.  7:1561-1568. 2001
  • Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.  7:2496-2504. 2001
  • Zinc α-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer.  7:846-853. 2001
  • Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas.  6:4017-4025. 2000
  • A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial.  6:3081-3087. 2000
  • Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.  6:597-601. 2000
  • Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells.  6:4442-4448. 2000
  • Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.  6:34-41. 2000
  • Selectivity of tag-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro.  6:4323-4333. 2000
  • Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.  5:3906-3913. 1999
  • 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma..  5:3330s-3336s. 1999
  • A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy..  5:3044s-3047s. 1999
  • Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts..  5:2994s-3000s. 1999
  • Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model..  5:3153s-3159s. 1999
  • Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A..  5:3243s-3248s. 1999
  • Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer..  5:3254s-3258s. 1999
  • Strategies for developing effective radioimmunotherapy for solid tumors..  5:3219s-3223s. 1999
  • Targeting strategies for cancer radiotherapy..  5:3048s-3055s. 1999
  • Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration.  5:2330-2337. 1999
  • Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.  5:2571-2579. 1999
  • Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.  5:1786-1792. 1999
  • Decreased expression of retinoic acid receptors, transforming growth factor β, involucrin, and cornifin in cervical intraepithelial neoplasia.  5:1503-1508. 1999
  • Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virus.  5:1517-1522. 1999
  • Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.  5:985-990. 1999
  • 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma..  5:533-541. 1999
  • 67Cu- versus 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.  5:533-541. 1999
  • In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.  5:383-393. 1999
  • Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy.  5:43-50. 1999
  • Biodistribution Study of 188Re-Labeled Trisuccin-HuCC49 and Trisuccin-HuCC49ΔCH2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer Xenografts.  5. 1999
  • Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.  4:2903-2912. 1998
  • Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.  4:2455-2461. 1998
  • Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.  4:2483-2490. 1998
  • Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy.  4:325-329. 1998
  • Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary.  4:265-270. 1998
  • Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas.  3:2157-2164. 1997
  • Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.  3:1253-1260. 1997
  • Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo.  3:1187-1194. 1997
  • Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).  3:71-79. 1997
  • Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.  2:1811-1818. 1996
  • Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.  2:1089-1095. 1996
  • Adenoviral-Mediated Delivery of the Herpes Simplex Virus Thymidine Kinase Gene Selectively Sensitizes Human Ovarian Carcinoma Cells to Ganciclovir.  1:1571-1580. 1995
  • Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor α in the Progression of Prostatic Neoplasms.  1:545-550. 1995
  • International Standard Serial Number (issn)

  • 1078-0432
  • Electronic International Standard Serial Number (eissn)

  • 1557-3265